GlaxoSmithKline PLC's poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) could have an edge over rivals as a first-line maintenance therapy in ovarian cancer based on results from the positive Phase III PRIMA trial in the broad population.
The double-blind, placebo-controlled study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status, GSK reported on 15 July. AstraZeneca PLC and Merck & Co. Inc.